Fig 1: Hdac2 and/or Ptp1b silencing efficiency and effect on cell viability. Positive and negative control (transfection without or with scrambled siRNA). Hdac2-siRNA, Ptp1b-siRNA, and Ptp1b-Hdac2-siRNA (transfection with siRNA against Hdac2, Ptp1b, or Ptp1b-Hdac2). The MTT absolute control value of absorbance at 562 nm was 0.80 ± 0.018. MTT analysis (A). Hdac2 and Ptp1b gene expression analysis (B,C). Data show the mean (n = 9) ± SEM of three independent experiments from cells of different cultures, each developed in triplicate. There were no significant differences between controls treated with and without a vehicle, cells transfected without siRNA or with scramble siRNA, or cells transfected with or without siRNA and treated with a vehicle in any of the targets studied. The data shown in the figures represent control treated with vehicle and transfected without siRNA as 100%. One-way (treatment-response comparisons) and two-way (transfection/treatment comparisons) ANOVA analyses followed by Tukey post-hoc test were developed to determine statistically significant differences between treatments. *** p ≤ 0.001, significantly different from controls.
Fig 2: BPA (0. 1 µM) cell viability (A) and apoptosis (B) effects on transfected or non-transfected SN56 cells with siRNA against Hdac2 and/or Ptp1b either alone or in combination with MK-801 (20 µM) and/or rβ-Catenin (15 µM) following 1- or 14-days. The data represent the mean (n = 9) ± SEM of three separate experiments from cells of different cultures, each of them performed in triplicate. There were no significant differences between controls treated with and without a vehicle, cells transfected without siRNA or with scramble siRNA, or cells transfected with or without siRNA and treated with a vehicle in any of the targets studied. The data shown in the figures represent control treated with vehicle and transfected without siRNA as 100%. One-way (treatment-response comparisons) and two-way (transfection/treatment comparisons) ANOVA analyses followed by Tukey post-hoc test were developed to determine statistically significant differences between treatments. *** p ≤ 0.001 compared to the control; ### p ≤ 0.001 compared to BPA treatment; &&& p ≤ 0.001 compared to BPA co-treatment with rβ-Catenin; γγγ p ≤ 0.001 compared to BPA treatment of Ptp1b silenced cells; τττ p ≤ 0.001 compared to Hdac2 knockdown cells exposed to BPA.
Supplier Page from MyBioSource.com for Mouse Protein tyrosine phosphatase 1B ELISA Kit